Patients with dihydralazine hepatotoxicity have been found to have circulating autoantibodies that react with liver microsomes (anti-liver microsome antibodies) and that are clearly distinct from anti-liver and kidney microsomal antibodies observed in patients with tienilic acid-induced hepatitis and in some patients with autoimmune hepatitis. The authors show that anti-liver microsome antibodies present in the sera of five patients with dihydralazine-induced hepatitis specifically react on immunoblots with a 53 kD protein. They further conclude that this target antigen is the phase I drug metabolizing enzyme termed P-450IA2 based on the following observations: (a) immunoblots of a battery of human liver microsomes produced the identical pattern of relative staining whether the blots were developed with anti-rat P-450IA2 IgG, anti-human P-450IA2 IgG or each of the five patients' sera; (b) P-450IA2 catalytic activity was selectively inhibited when human liver microsomes were preincubated with anti-liver microsome-positive sera; (c) anti-liver microsome-positive sera identified purified human P-450IA2 on immunoblots. Anti-liver microsome antibodies appeared to be specific for dihydralazine hepatitis because they were not present in sera obtained from 28 other patients including patients receiving dihydralazine without a toxic response and patients with other significant liver diseases. Finally, the authors demonstrated that dihydralazine could competitively inhibit catalytic activity characteristic of P-450IA2 in human liver microsomes, suggesting that P-450IA2 may be involved in the metabolism of dihydralazine.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.